
Therapeutic Antibodies
Therapeutic Monoclonal Antibodies Therapeutic antibodies are developed for the treatment of human diseases. Their therapeutic function is proven in clinical trials and they are registered
Products & Services
Drug Aliquots – on stock (original buffer)
CoA – Certificates of Analysis
Drug aliquots – on demand (custom aliquotation)
Drug vials (procurement service)
Dilutions (diluted drug aliquots, 1mg/ml, PBS)
As a leading custom service provider specialized in the supply of therapeutic antibodies for analytical research, Evidentic is happy to support young and ambitious talents in our field.
$1500 paid via paypal or wiretransfer. Winner will be chosen on March 31, of every year
To select the unique student who best meets all the requirements above, Evidentic Scholarship Program sets up two phases of selections.
(click on the topic to expand and read more details)
Describe patents, their importance in the context of patents of drugs/medicine by the pharmaceutical industry. Are patents necessary? What can be the alternate? What happens when the patents expire? How is the patent expiry related to biosimilars and generics?
Describe therapeutic antibodies. What are the new therapeutic antibodies approved in the last year or two? for which therapeutic area? Why new development is necessary and what makes it valuable? What are the latest developments in the field of therapeutic antibodies in the last 2 years? How does the future look like for therapeutic antibodies?
What are antibodies? Their role in the body’s immune system. Why are they a good tool in research experiments? For which research experiments antibodies can they be used? How can you judge/find out about the quality of the antibody? What do you think – should one choose therapeutic antibodies over research antibodies for bench work? Why or why not?
How can the immune system be exploited to produce medicines against cancer? What are the current immune-therapies available to patients now? What are the emerging technologies in the field of immune-oncology? How do therapeutic antibodies fit into this vast paradigm of immuno-oncology therapies?
Example fields: Rheumatoid arthritis, asthma, infectious disease, autoimmune disorders, etc. Why did you choose this field? Describe how the treatment evolved in this field? What is the current treatment in this field? How did therapeutic antibodies change the field? Is the treatment with therapeutic antibodies better why or why not? [Hint EMA + disease condition]
Drug aliquots are the products of Evidentic. What are biosimilars? What is a biosimilar comparability exercise? What is a reference drug? Why different batches of drugs are needed for biosimilar development? Who approves the biosimilar drugs? Any ideas on how the product of Evidentic – “Drug Aliquots” might fit in this approval process? Hint: FDA biosimilar draft guideline -2019 (https://www.fda.gov/media/125484/download)
Therapeutic Monoclonal Antibodies Therapeutic antibodies are developed for the treatment of human diseases. Their therapeutic function is proven in clinical trials and they are registered